Our Facilities & Pipeline
Duopharma Biotech has three R&D and manufacturing facilities across the Klang Valley in Malaysia – in Klang, Bangi and Glenmarie.
Klang
The facility in Klang is a GMP-certified factory pioneering advanced pharmaceutical technologies, manufacturing Halal pharmaceutical products comprising a wide array of tablets, capsules, syrups, oral antibiotic creams, solutions for haemodialysis and sterile irrigation, sterile powders, injectables, small volume injectables, dental cartridges and eye drop preparations – for the local and export markets. In addition, R&D and stability studies of different formulations are also conducted here.
Bangi
Glenmarie, Shah Alam
Located in Glenmarie, Shah Alam, this facility serves as a key innovation hub for Duopharma Biotech. It houses a team of over 30 multi-disciplinary scientists dedicated to the research and development of high-quality, safe, and efficacious pharmaceutical products to meet the evolving needs of patients and the healthcare industry.
The ISO/IEC 17025-accredited facility is equipped with advanced laboratory technologies, including high-performance liquid chromatography (HPLC) machines, ultra-performance liquid chromatography (UPLC) units, dissolution testers and lab-scale formulation system. A notable achievement includes the successful development of OMESEC mini-tablet capsules, recognised as the Best Innovative Product by the Ministry of Investment, Trade and Industry (MITI) Malaysia in 2001.
The Glenmarie facility is also home to Malaysia’s first facility dedicated for the manufacture of Highly Potent Active Ingredients (HAPI). Purpose-built for the production of complex, high-value generics across therapeutic areas such as cardiovascular, musculoskeletal and oncology, the facility complies with stringent Good Manufacturing Practice (GMP) standards. In February 2025, it attained European Union (EU) GMP certification by the Health Products Regulatory Authority (HPRA), Ireland — a significant milestone that strengthens our global export capabilities and alignment with international regulatory requirements.
These facilities reflect Duopharma Biotech’s commitment to innovation, product excellence and global competitiveness in delivering smarter solutions for a healthier life.
Our Pipeline
Duopharma Biotech’s pipeline reflects our focus on high-value niche areas such as digital health, regenerative medicine, neurodegenerative diseases and biotherapeutics.
We aim to lead the way in the industry and are exploring less-prominent fields such as therapies for rare and orphan diseases, 4D bioprinting or digital diagnostics.
We see the pharmaceutical industry moving towards patient-centric value creation, where digital transformation supports individual healthcare providers as well as the healthcare ecosystem holistically, improving how the system works, developing ease of access to services, and enhancing patient and clinician experience. Medical prognostic, diagnostic and therapeutic technologies such as biotechnology, gene and cell therapy and precision medicine will gain wider application and prominence, in turn transforming the medical sector.